Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography

Circ J. 2009 Dec;73(12):2300-7. doi: 10.1253/circj.cj-08-1116. Epub 2009 Sep 29.

Abstract

Background: Late stent thrombosis related to delayed neointimal growth is a major concern after drug-eluting stent (DES) implantation. The time course of neointimal growth and risk factors of uncovered stent struts after sirolimus-eluting stent (SES) was studied using optical coherence tomography (OCT).

Methods and results: The 60 patients were enrolled and classified into G1 (follow-up period <9 months, n=27), G2 (9-24 months, n=18), and G3 (>25 months, n=15). The time elapsed since SES implantation was associated with a significant increase in mean neointimal area and neointimal thickness, and also with a significant decrease in the number of uncovered stent struts (G1: 14.8%, G2: 11.7%, and G3: 4.1%, P<0.001). However, only 17.6% of implanted SES was completely covered by neointima, even in the G3 period. Small-diameter SES, complex coronary lesions with lipid and calcium content adjacent to stent struts, and diabetes predicted delayed neointimal coverage of SES struts in G1.

Conclusions: Neointima inside SES progressively increases after the routine follow-up period, but only a few SES were completely covered at 3 years after implantation. OCT is a useful modality for assessing neointimal formation after SES implantation, and may give important information about the strategy of antiplatelet therapy after DES implantation.

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Cardiovascular Agents / administration & dosage*
  • Cell Proliferation
  • Coronary Angiography
  • Coronary Vessels / pathology*
  • Drug-Eluting Stents*
  • Female
  • Follow-Up Studies
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Risk Assessment
  • Risk Factors
  • Sirolimus / administration & dosage*
  • Thrombosis / etiology
  • Thrombosis / pathology
  • Thrombosis / prevention & control*
  • Time Factors
  • Tomography, Optical Coherence*
  • Treatment Outcome
  • Tunica Intima / pathology*

Substances

  • Cardiovascular Agents
  • Platelet Aggregation Inhibitors
  • Sirolimus